QNCX
Quince Therapeutics, Inc. NASDAQ Listed May 9, 2019$1.30
Mkt Cap $7.2M
52w Low $0.80
1.1% of range
52w High $45.50
50d MA $1.16
200d MA $15.40
P/E (TTM)
-0.1x
EV/EBITDA
-3.6x
P/B
—
Debt/Equity
-0.5x
ROE
235.1%
P/FCF
-4.0x
RSI (14)
—
ATR (14)
—
Beta
1.33
50d MA
$1.16
200d MA
$15.40
Avg Volume
10.7M
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
601 Gateway Blvd · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2025 | AMC | -0.20 | -0.25 | -25.0% | 17.10 | -0.6% | -1.8% | -1.8% | +5.3% | +11.7% | +12.9% | — |
| Aug 11, 2025 | AMC | -0.28 | -0.34 | -21.4% | 16.00 | -1.2% | +14.4% | +7.5% | +5.0% | +5.6% | +4.4% | — |
| May 13, 2025 | AMC | -0.24 | -0.34 | -41.7% | 9.50 | +1.1% | -11.5% | -11.7% | -10.5% | -0.1% | +7.4% | — |
| Mar 24, 2025 | AMC | -0.19 | -0.28 | -47.4% | 14.00 | -2.9% | -2.1% | -4.3% | +0.0% | -3.6% | -5.0% | — |
| Nov 13, 2024 | AMC | -0.17 | -0.13 | +25.0% | 15.90 | -1.9% | +19.5% | +11.9% | +10.1% | +11.3% | +15.7% | — |
| Aug 13, 2024 | AMC | — | -0.18 | — | 5.76 | +0.7% | -4.5% | -6.2% | -4.7% | +5.9% | +5.9% | — |
| May 13, 2024 | AMC | — | -0.26 | — | 9.20 | -2.2% | -1.1% | -1.3% | +0.0% | -1.6% | -2.2% | — |
| Mar 11, 2024 | AMC | -0.28 | -0.22 | +21.4% | 11.70 | +0.0% | +2.6% | +0.9% | -0.9% | -0.9% | +1.7% | — |
| Nov 14, 2023 | AMC | — | -0.15 | — | 8.97 | +0.3% | -0.8% | -0.3% | -4.1% | -1.9% | -2.9% | — |
| Aug 3, 2023 | AMC | — | -0.14 | — | 12.30 | +0.0% | -1.6% | -1.6% | -0.8% | -1.6% | +0.8% | — |
| May 15, 2023 | AMC | -0.31 | -0.34 | -10.0% | 15.40 | -1.3% | +1.3% | +3.2% | +5.8% | +7.1% | +5.8% | — |
| Mar 15, 2023 | AMC | -0.29 | -0.13 | +54.8% | 8.51 | -2.5% | -1.3% | -2.5% | -1.1% | +69.2% | +70.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 30 | D. Boral Capital | Downgrade | Buy → Hold | — | $2.70 | $2.50 | -7.4% | -37.0% | -33.3% | -46.3% | -41.1% | -45.9% |
| Jan 30 | Citizens | Downgrade | Market Outperform → Market Perform | — | $2.70 | $2.50 | -7.4% | -37.0% | -33.3% | -46.3% | -41.1% | -45.9% |
| Jan 29 | D. Boral Capital | Maintains | Buy → Buy | — | $31.80 | $31.40 | -1.3% | -91.5% | -94.7% | -94.3% | -95.4% | -95.0% |
| Dec 15 | D. Boral Capital | Maintains | Buy → Buy | — | $42.20 | $42.50 | +0.7% | -10.7% | -12.3% | -11.8% | -17.5% | -15.4% |
| Nov 13 | D. Boral Capital | Maintains | Buy → Buy | — | $17.10 | $17.00 | -0.6% | -1.8% | -1.8% | +5.3% | +11.7% | +12.9% |
| Sep 26 | D. Boral Capital | Maintains | Buy → Buy | — | $16.30 | $16.30 | +0.0% | -1.2% | -1.2% | +0.0% | -0.6% | +0.6% |
| Aug 15 | D. Boral Capital | Maintains | Buy → Buy | — | $16.80 | $16.80 | +0.0% | +0.6% | -0.6% | -4.2% | -3.0% | -4.2% |
| Aug 12 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $16.00 | $15.80 | -1.2% | +14.4% | +7.5% | +5.0% | +5.6% | +4.4% |
| Jul 17 | D. Boral Capital | Maintains | Buy → Buy | — | $16.80 | $16.50 | -1.8% | +8.9% | +12.5% | +13.1% | +5.4% | +10.7% |
| Jun 13 | D. Boral Capital | Maintains | Buy → Buy | — | $12.00 | $12.00 | +0.0% | +19.2% | +15.0% | +13.3% | +13.3% | +8.3% |
| Jun 4 | D. Boral Capital | Maintains | Buy → Buy | — | $10.50 | $10.80 | +2.9% | +3.8% | +13.3% | +11.4% | +11.4% | +14.3% |
| Mar 25 | D. Boral Capital | Maintains | Buy → Buy | — | $14.00 | $13.60 | -2.9% | -2.1% | -4.3% | +0.0% | -3.6% | -5.0% |
| Feb 5 | D. Boral Capital | Maintains | Buy → Buy | — | $15.50 | $15.30 | -1.3% | +7.7% | +1.9% | -4.5% | -7.7% | -9.7% |
| Jan 2 | D. Boral Capital | Maintains | Buy → Buy | — | $18.70 | $18.80 | +0.5% | +0.5% | +4.3% | +6.4% | +3.7% | +0.5% |
| Nov 14 | D. Boral Capital | Maintains | Buy → Buy | — | $15.90 | $15.60 | -1.9% | +19.5% | +11.9% | +10.1% | +11.3% | +15.7% |
| Nov 12 | D. Boral Capital | Maintains | Buy → Buy | — | $16.60 | $16.70 | +0.6% | +1.2% | -4.2% | +14.5% | +7.2% | +5.4% |
| May 10 | Credit Suisse | Maintains | Underperform → Underperform | — | $32.80 | $35.00 | +6.7% | +13.4% | -4.3% | +2.4% | +3.0% | +3.4% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.50 | $43.20 | +1.6% | +8.2% | +13.4% | +12.0% | +11.8% | +12.7% |
| Jan 27 | Canaccord Genuity | Downgrade | Buy → Hold | — | $62.10 | $61.08 | -1.6% | -10.0% | -3.7% | -2.1% | +10.0% | -0.8% |
| Jan 27 | JMP Securities | Downgrade | Market Outperform → Perform | — | $62.10 | $61.08 | -1.6% | -10.0% | -3.7% | -2.1% | +10.0% | -0.8% |
| Jan 26 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $90.60 | $57.50 | -36.5% | -31.5% | -38.3% | -34.0% | -32.9% | -24.6% |
| Oct 26 | BofA Securities | Downgrade | Neutral → Underperform | — | $592.70 | $596.40 | +0.6% | -2.7% | -77.2% | -75.9% | -77.7% | -76.0% |
| Oct 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $592.70 | $596.40 | +0.6% | -2.7% | -77.2% | -75.9% | -77.7% | -76.0% |
| Sep 15 | Canaccord Genuity | Maintains | Buy → Buy | — | $842.30 | $843.00 | +0.1% | -0.3% | +7.3% | +4.2% | +1.7% | +2.8% |
| Aug 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $957.30 | $957.50 | +0.0% | -2.9% | +6.7% | +10.6% | +8.8% | +0.6% |
| Feb 16 | Jefferies | Downgrade | Buy → Hold | — | $474.70 | $367.88 | -22.5% | -35.3% | -34.4% | -33.7% | -31.6% | -32.9% |
| Dec 6 | BofA Securities | Upgrade | Neutral → Buy | — | — | — | — | — | — | — | — | — |
| Sep 16 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | — | — | — | — | — | — | — | — |
No insider trades available.
8-K
Quince Therapeutics, Inc. -- 8-K Filing
Quince Therapeutics appointed a new director who will receive a $38,000 annual retainer plus additional compensation for committee service, strengthening board governance oversight.
Apr 22
8-K
Unknown — 8-K Filing
A reverse stock split typically signals financial distress or delisting risk, as companies use this tactic to meet minimum stock price requirements, potentially diluting shareholder value through fractional share cash-outs.
Apr 9
NT 10-K
!!! Very High
Unknown — Late Annual Report — Distress Signal
QNCX's late annual report filing signals potential financial distress or operational issues, likely causing regulatory penalties and investor concern about governance, liquidity, or viability.
Apr 1
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
The 8-K filing provides limited disclosure details, but investors should monitor QNCX for the actual regulatory announcement that triggered this Regulation FD statement regarding material information.
Mar 30
8-K
Unknown — 8-K Filing
QNCX faces potential delisting from Nasdaq unless it meets minimum bid price requirements, but can transfer to Nasdaq Capital Market if it satisfies other listing standards and pays applicable fees.
Mar 20
8-K · 8.01
!! High
Quince Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Quince Therapeutics engaged LifeSci Capital to explore restructuring and strategic alternatives, including a potential reverse merger, to maximize shareholder value.
Feb 12
8-K
Quince Therapeutics, Inc. -- 8-K Filing
Quince Therapeutics (QNCX) filed an 8-K with the SEC, likely disclosing a material event, though the specific details are unclear from this technical documentation reference.
Feb 2
Data updated apr 26, 2026 9:33pm
· Source: massive.com